- Home
- FORR vs NKTX Comparison
FORR vs NKTX Comparison
Compare FORR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- NKTX
- Stock Information
- Founded
- FORR 1983
- NKTX 2015
- Country
- FORR United States
- NKTX United States
- Employees
- FORR N/A
- NKTX N/A
- Industry
- FORR Diversified Commercial Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- NKTX Health Care
- Exchange
- FORR Nasdaq
- NKTX Nasdaq
- Market Cap
- FORR 169.1M
- NKTX 147.7M
- IPO Year
- FORR 1996
- NKTX 2020
- Fundamental
- Price
- FORR $7.42
- NKTX $1.82
- Analyst Decision
- FORR
- NKTX Strong Buy
- Analyst Count
- FORR 0
- NKTX 5
- Target Price
- FORR N/A
- NKTX $13.25
- AVG Volume (30 Days)
- FORR 132.1K
- NKTX 896.4K
- Earning Date
- FORR 10-30-2025
- NKTX 11-10-2025
- Dividend Yield
- FORR N/A
- NKTX N/A
- EPS Growth
- FORR N/A
- NKTX N/A
- EPS
- FORR N/A
- NKTX N/A
- Revenue
- FORR $403,871,000.00
- NKTX N/A
- Revenue This Year
- FORR N/A
- NKTX N/A
- Revenue Next Year
- FORR $1.04
- NKTX N/A
- P/E Ratio
- FORR N/A
- NKTX N/A
- Revenue Growth
- FORR N/A
- NKTX N/A
- 52 Week Low
- FORR $7.07
- NKTX $1.31
- 52 Week High
- FORR $17.65
- NKTX $3.16
- Technical
- Relative Strength Index (RSI)
- FORR 35.15
- NKTX 34.67
- Support Level
- FORR $7.38
- NKTX $1.85
- Resistance Level
- FORR $8.08
- NKTX $2.05
- Average True Range (ATR)
- FORR 0.46
- NKTX 0.11
- MACD
- FORR 0.01
- NKTX -0.03
- Stochastic Oscillator
- FORR 12.36
- NKTX 2.04
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.